TY - JOUR T1 - Assessing the role of polygenic background on the penetrance of monogenic forms in Parkinson’s disease JF - medRxiv DO - 10.1101/2021.06.06.21253270 SP - 2021.06.06.21253270 AU - Emadeldin Hassanin AU - Patrick May AU - Rana Aldisi AU - Peter Krawitz AU - Carlo Maj AU - Dheeraj Reddy Bobbili Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/06/09/2021.06.06.21253270.abstract N2 - Background Several rare and common variants are associated with Parkinson’s disease. However, there is still an incomplete penetrance in the carriers of rare variants associated with Parkinson’s disease. To address this issue, we investigated whether a PRS calculated from significant GWAS SNPs affects the penetrance of Parkinson’s disease among carriers of rare monogenic variants in known Parkinson’s disease genes and those with a family history.Methods We calculated the PRS based on common variants and selected the carriers of rare monogenic variants by using the exome data from UK Biobank. Individuals were divided into three risk categories based on PRS: low (<10%), intermediate (10%-90%), and high (>90%) risk groups. We then compared how PRS affects Parkinson’s disease risk among carriers of rare monogenic variants and those with family-history.Results We observed a two-fold higher odds ratio for a carrier of a monogenic variant that had a high PRS (OR 4.07,95% CI, 1.72-8.08) compared to carriers with a low PRS (OR 1.91, 95% CI, 0.31-6.05). In the same line, carriers with a first-degree family history and with >90% PRS have even a higher risk of developing PD (OR 23.53, 95%CI 5.39-71.54) compared to those with <90% PRS (OR 9.54, 95% CI 3.32-21.65).Conclusions Our results show that PRS, carrier status, and family history contribute independently and additively to the Parkinson’s disease risk.Competing Interest StatementThe authors have declared no competing interest.Funding StatementD.R.B. is supported by the Industrial fellowship program (FNR14323864) of the Fonds National de Recherche (FNR) Luxembourg. The FNR supported P.M. as part of the National Centre of Excellence in Research on Parkinson's disease (NCER-PD, FNR11264123) and the DFG Research Units FOR2715 (INTER/DFG/17/11583046) and FOR2488 (INTER/DFG/19/14429377). C.M. and E.H. are supported by the BONFOR-program of the Medical Faculty, University of Bonn (O-147.0002). The authors acknowledge the use of de.NBI cloud and the support by the High Performance and Cloud Computing Group at the Zentrum fur Datenverarbeitung of the University of Tubingen and the Federal Ministry of Education and Research (BMBF) through grant no 031A535A.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:I confirm all relevant ethical guidelines have been followed.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesGenome-wide genotyping data, exome-sequencing data, and phenotypic data from the UK Biobank and Parkinson's Progression Markers Initiative (PPMI) are available upon successful project application. https://www.ukbiobank.ac.uk/ https://www.ppmi-info.org/ ER -